tailieunhanh - báo cáo khoa học: "Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights | Zhu et al. Journal of Hematology Oncology 2010 3 17 http content 3 1 17 JOURNAL OF HEMATOLOGY ONCOLOGY REVIEW Open Access Novel agents and regimens for acute myeloid leukemia 2009 ASH annual meeting highlights Xiongpeng Zhu 1 2 Yuehua Ma2 and Delong Liu 2 Abstract Prognostic markers such as NPM1 Flt3-ITD and cytogenetic abnormalities have made it possible to formulate aggressive treatment plans for unfavorable acute myeloid leukemia AML . However the long-term survival of AML with unfavorable factors remains unsatisfactory. The latest data indicate that the standard dose of daunorubicin DNR at 45 mg m2 is inferior to high dose 90 mg m2 for induction therapy. The rates of complete remission and overall survival are significantly better in the high dose induction regimen. New regimens exploring the new liposomal encapsulation of Ara-C and DNR as well as addition of gemtuzumab ozogamicin monoclonal antibody have been studied. New agents including the nucleoside analogues clofarabine sapacitabine elacytarabine FLT3 inhibitor sorafenib farnesyl-transferase inhibitor tipifarnib histone deacetylase inhibitor vorinostat lenalidomide as well as DNA methyltransferase inhibitors decitabine azacitidine were recently reported for AML treatment in the 2009 ASH annual meeting. This review also summarizes the updates of the clinical trials on novel agents including voreloxin AS1413 behenoylara-C ARRY520 ribavirin AZD1152 AZD6244 and terameprocol EM-1421 from the 2009 ASH annual meeting. Introduction Acute myeloid leukemia AML is the most common type of acute leukemia in adults. Over the past twenty years the studies on the pathogenesis and prognosis of AML have made revolutionary progress. However only one-third of adult AML can be cured even to this date. The treatment of refractory relapsed and elderly AML remains a major challenge. In recent years new regimens and novel agents are being studied in an effort to improve complete remission CR rate and overall .